MedPath

A Multicenter phase II study of Carboplatin/Pemetrexed/Bevacizumab in First-Line Treatment of Elderly Patients with Advanced Non-squamous and Non-small Cell Lung cancer

Phase 2
Conditions
on-squamous non-small cell lung cancer
Registration Number
JPRN-UMIN000011095
Lead Sponsor
Kurume University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
42
Inclusion Criteria

Not provided

Exclusion Criteria

1) The case that there is previous treatment history 2) With the active double primary cancer 3) With the pleural effusion or pericardial effusion to need drainage 4) With the metastatic brain tumor to need treatment, such as radiotherapy or steroid 5) History of active hemoptysis with 2,5 ml or more 6) The case that a hemorrhage risk is high a) With the necessity of the administration of anticoagulant and antiplatelet agent b) With the the tumor invasion to great vessels c) With the cavity lesion 7) With the following complication or past history a) With the merger or history of cerebrovascular disease to need treatment b) With the history of perforation gastrointestinal, fistula, diverticulitis c) With the diarrhea, paresis of intestine, ileus d) With the merger or history of angina or myocardial infarction, cardiac failure to need treatment e) With the uncontrol diabetes f) With the interstitial pneumonia g) With the uncontrol infectious disease h) With the history of serious drug allergy i) With the uncontrol hypertension even if taking the hypotensive drug 8) With the mental disease 9) The patient whom attending physician judged to be inadequate to perform the study treatment safely

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath